A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two
formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults.
Parts I to IV of this study will examine different doses of MK-0517 as well as two different
formulations of MK-0517 (with and without polysorbate 80). Part V of the study will compare
single doses of intravenous non-PS80 MK-0517 to oral 125-mg capsule of aprepitant. The
primary hypothesis for Part V of the study is that a single intravenous dose of 100-mg or
115-mg MK-0517 is area under the plasma-time curve (AUC) equivalent to that of the 125-mg
oral aprepitant capsule in young healthy participants.